Assessing the clinical, humanistic, and economic impact of early cancer diagnosis: a systematic literature review
Open accessThe DOI matches its Crossref record; 105 of the 107 references it cites were found in a registry or an index.
Abstract
Introduction: There is a clear consensus among healthcare providers on the advantages of early cancer detection and treatment. However, no in-depth review has yet fully presented the clinical, humanistic, and economic benefits of early cancer diagnosis compared to late detection across a broad range of tumor types. Methods: A systematic literature review was conducted to determine the clinical, humanistic, and economic benefits of early cancer diagnosis, as opposed to late diagnosis, as reported in non-interventional studies conducted worldwide. Searches were conducted using electronic databases (MEDLINE and Embase), conference repositories and grey literature. Observational studies in adults diagnosed with bladder cancer, gastric cancer, head and neck cancer (HNC), melanoma, non-small cell lung cancer (NSCLC), renal-cell carcinoma (RCC), and triple negative breast cancer (TNBC) were eligible for inclusion if they reported survival, health-related quality of life (HRQoL), healthcare resource utilization and/or costs, according to stage at diagnosis. Identified records were screened and extracted by two independent reviewers, and discrepancies were resolved by a third reviewer. The quality of studies was assessed using the Newcastle-Ottawa scale and the Larg and Moss adapted checklist. Results: Of the 3,159 records identified, 103 studies were included in this review. The general trend showed worse clinical, humanistic, and economic outcomes when patients were diagnosed at a later stage compared to an earlier stage. Patients diagnosed at an earlier stage, had on average, substantially higher survival rates and lower mortality rates across all cancer types and incurred lower resource utilization and costs (with available evidence for patients with NSCLC, TNBC, and HNC), compared to those diagnosed at a more advanced/later stage. Limited evidence on the humanistic burden suggested that with a more advanced stage at diagnosis, patients with bladder cancer experienced reduced HRQoL. Conclusion: Early cancer diagnosis (i.e., cancer diagnosed at earlier stages or with lower grades) was associated with longer survival, improved quality of life and lower healthcare costs and resource utilization compared to diagnosis of cancer at later stages or higher grades, as reported by overall survival (OS) and HRQoL outcomes. These findings emphasize the importance of screening and early detection of cancer to improve outcomes among patients diagnosed with cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As melanoma has the highest mortality among skin cancers, particularly when diagnosis is delayed, early detection is crucial to promote public health, reduce economic costs of health care, and improve patient outcomes (180, 181).”
From Diagnostic accuracy of teledermatology for skin diseases: a systematic review and meta-analysis (2026) · cites this paper as [181]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As melanoma has the highest mortality among skin cancers, particularly when diagnosis is delayed, early detection is crucial to promote public health, reduce economic costs of health care, and improve patient outcomes (180, 181).”
From Diagnostic accuracy of teledermatology for skin diseases: a systematic review and meta-analysis (2026) · cites this paper as [181]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024) · CA: a cancer journal for clinicians · doi:10.3322/caac.21834 · Cited by 27,064
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · Systematic Reviews · doi:10.1186/s13643-021-01626-4 · Cited by 13,874 · cited 1×
“A systematic review was conducted following the guidelines in the Cochrane Handbook for Systematic Reviews and the Centre for Reviews and Dissemination (28, 29) and was reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) (30).”
Pembrolizumab for Early Triple-Negative Breast Cancer
Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910549 · Cited by 3,270
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
Forde, P. M., Spicer, J., Lu, S., Provencio, M., Mitsudomi, T., Awad, M. M., Felip, E., Broderick, S. R., Brahmer, J. R., Swanson, S. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2202170 · Cited by 2,825
Mortality due to cancer treatment delay: systematic review and meta-analysis
Hanna, T. P., King, W. D., Thibodeau, S., Jalink, M., Paulin, G. A., Harvey-Jones, E., O’Sullivan, D. E., Booth, C. M., Sullivan, R., & Aggarwal, A. (2020) · BMJ · doi:10.1136/bmj.m4087 · Cited by 1,742
Crosby, D., Bhatia, S., Brindle, K. M., Coussens, L. M., Dive, C., Emberton, M., Esener, S., Fitzgerald, R. C., Gambhir, S. S., Kuhn, P., et al. (2022) · Science · doi:10.1126/science.aay9040 · Cited by 1,379 · cited 1×
“…at the time of diagnosis varies across cancer types, and despite advances in diagnostic tools, the majority of patients diagnosed with certain cancer types (for example, lung, pancreatic and ovarian cancers) are still detected at an advanced stage, leading to poor prognoses and outcomes (11, 12).”
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
Wakelee, H., Liberman, M., Kato, T., Tsuboi, M., Lee, S.-H., Gao, S., Chen, K.-N., Dooms, C., Majem, M., Eigendorff, E., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2302983 · Cited by 1,180
Neal, R. D., Tharmanathan, P., France, B., Din, N. U., Cotton, S., Fallon-Ferguson, J., Hamilton, W., Hendry, A., Hendry, M., Lewis, R., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.48 · Cited by 999
Pulte, D., & Brenner, H. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0289 · Cited by 849
O’Brien, M., Paz-Ares, L., Marreaud, S., Dafni, U., Oselin, K., Havel, L., Esteban, E., Isla, D., Martinez-Marti, A., Faehling, M., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00518-6 · Cited by 774
Luke, J. J., Rutkowski, P., Queirolo, P., Del Vecchio, M., Mackiewicz, J., Chiarion-Sileni, V., de la Cruz Merino, L., Khattak, M. A., Schadendorf, D., Long, G. V., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00562-1 · Cited by 499
Cost-of-Illness Studies: A Guide to Critical Evaluation
Larg, A., & Moss, J. R. (2011) · PharmacoEconomics · doi:10.2165/11588380-000000000-00000 · Cited by 404 · cited 1×
“Quality assessment was conducted using the Newcastle-Ottawa Scale (observational studies) and the adapted Larg and Moss checklist (cost-of-illness studies) (45, 46).”
Shitara, K., Rha, S. Y., Wyrwicz, L. S., Oshima, T., Karaseva, N., Osipov, M., Yasui, H., Yabusaki, H., Afanasyev, S., Park, Y.-K., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00541-7 · Cited by 384
Next-Generation Sequencing of Circulating Tumor DNA for Early Cancer Detection
Aravanis, A. M., Lee, M., & Klausner, R. D. (2017) · Cell · doi:10.1016/j.cell.2017.01.030 · Cited by 367
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma
Choueiri, T. K., Tomczak, P., Park, S. H., Venugopal, B., Ferguson, T., Symeonides, S. N., Hajek, J., Chang, Y.-H., Lee, J.-L., Sarwar, N., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2312695 · Cited by 346
Powles, T., Tomczak, P., Park, S. H., Venugopal, B., Ferguson, T., Symeonides, S. N., Hajek, J., Gurney, H., Chang, Y.-H., Lee, J. L., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00487-9 · Cited by 294
Felip, E., Altorki, N., Zhou, C., Vallières, E., Martínez-Martí, A., Rittmeyer, A., Chella, A., Reck, M., Goloborodko, O., Huang, M., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.07.001 · Cited by 263
Abdollah, F., Gandaglia, G., Thuret, R., Schmitges, J., Tian, Z., Jeldres, C., Passoni, N. M., Briganti, A., Shariat, S. F., Perrotte, P., et al. (2013) · Cancer Epidemiology · doi:10.1016/j.canep.2013.02.002 · Cited by 250 · cited 2×
“In bladder cancer, a trend analysis of SEER data from 148,315 patients diagnosed between 1973 and 2009 showed that stage-speci fi c fi ve-year survival rates were higher in patients diagnosed at localized and regional stages compared to distant stages (20).”
Kirkwood, J. M., Del Vecchio, M., Weber, J., Hoeller, C., Grob, J.-J., Mohr, P., Loquai, C., Dutriaux, C., Chiarion-Sileni, V., Mackiewicz, J., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02583-2 · Cited by 239
Wise-Draper, T. M., Gulati, S., Palackdharry, S., Hinrichs, B. H., Worden, F. P., Old, M. O., Dunlap, N. E., Kaczmar, J. M., Patil, Y., Riaz, M. K., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3351 · Cited by 197
Cho, H., Mariotto, A. B., Schwartz, L. M., Luo, J., & Woloshin, S. (2014) · JNCI Monographs · doi:10.1093/jncimonographs/lgu014 · Cited by 174 · cited 1×
“One of the proposed strategies to lessen cancer burden is to diagnose the disease as early as possible, as it is generally easier to treat cancer when it is localized as opposed to when it has spread, and results in better patient outcomes (4 – 6).”
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma
Apolo, A. B., Ballman, K. V., Sonpavde, G., Berg, S., Kim, W. Y., Parikh, R., Teo, M. Y., Sweis, R. F., Geynisman, D. M., Grivas, P., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2401726 · Cited by 168
Improving early diagnosis of symptomatic cancer
Hamilton, W., Walter, F. M., Rubin, G., & Neal, R. D. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.109 · Cited by 167
Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma
Eggermont, A. M. M., Kicinski, M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Meshcheryakov, A., Khattak, A., et al. (2022) · NEJM Evidence · doi:10.1056/evidoa2200214 · Cited by 160
Svedman, F. C., Pillas, D., Kaur, M., Linder, R., Hansson, J., & Taylor, A. (2016) · Clinical Epidemiology · doi:10.2147/clep.s99021 · Cited by 127
Potter, A. L., Rosenstein, A. L., Kiang, M. V., Shah, S. A., Gaissert, H. A., Chang, D. C., Fintelmann, F. J., & Yang, C.-F. J. (2022) · BMJ · doi:10.1136/bmj-2021-069008 · Cited by 127
Association of Stage Shift and Population Mortality Among Patients With Non–Small Cell Lung Cancer
Flores, R. M., Patel, P. B., Alpert, N., Pyenson, B. S., & Taioli, E. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.37508 · Cited by 120
Increased healthcare costs by later stage cancer diagnosis
McGarvey, N. H., Gitlin, M. D., Fadli, E., & Chung, K. (2022) · BMC Health Services Research · doi:10.1186/s12913-022-08457-6 · Cited by 116
Qiu, M., Shi, S., Chen, Z., Yu, H., Sheng, H., Jin, Y., Wang, D., Wang, F., Li, Y., Xie, D., et al. (2018) · Cancer Medicine · doi:10.1002/cam4.1661 · Cited by 114
A retrospective analysis of delays in the diagnosis of lung cancer and associated costs
Gildea, T. R., Byfield, S. D., Hogarth, D. K., Wilson, D. S., & Quinn, C. C. (2017) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s132259 · Cited by 87 · cited 3×
“Three studies were included that reported the fi nancial impact of patients diagnosed with NSCLC at different stages (Figure 4 Two studies reported HCRU in patients diagnosed with NSCLC (65, 117).”
InfluentialSpicer, J. D., Gao, S., Liberman, M., Kato, T., Tsuboi, M., Lee, S. H., Chen, K.-N., Dooms, C., Majem, M., Eigendorff, E., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.10.052 · Cited by 86
Survival after diagnosis of cancer of the oral cavity
Sargeran, K., Murtomaa, H. T., Safavi, S. M. R., Vehkalahti, M. M., & Teronen, O. P. (2007) · British Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.bjoms.2007.11.004 · Cited by 84 · cited 3×
“Of the six included studies that reported mOS and OS rates, two reported mOS (95, 96), whereas three included OS rates 5 years post-diagnosis (54, 93, 94).”
Overall survival in patients with metastatic melanoma
Song, X., Zhao, Z., Barber, B., Farr, A. M., Ivanov, B., & Novich, M. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1021904 · Cited by 70 · cited 2×
“Of the six studies that reported OS among patients diagnosed with melanoma according to stage at the time of diagnosis, three provided the mOS (59, 60, 108), and one reported OS rate 5 years post-diagnosis (108).”
InfluentialJazieh, A. R., Önal, C., Tan, D. S. W., Soo, R. A., Prabhash, K., Kumar, A., Huggenberger, R., Robb, S., & Cho, B. C. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.05.003 · Cited by 63
A prospective study to determine the cost of illness for oral cancer in India
Singh, A. G., Chaukar, D. A., Gupta, S., Pramesh, C. S., Sullivan, R. J., Chaturvedi, P., & Badwe, R. A. (2021) · ecancermedicalscience · doi:10.3332/ecancer.2021.1252 · Cited by 55 · cited 2×
“%) made up the bulk of the overall costs (55).”
Khadirnaikar, S., Shukla, S. K., & Prasanna, S. R. M. (2023) · Scientific Reports · doi:10.1038/s41598-023-31426-w · Cited by 54
Ho, P., Wang, W., Huang, Y.-T., & Yang, Y. (2018) · Oral Oncology · doi:10.1016/j.oraloncology.2018.12.007 · Cited by 52
Wood, R., Taylor-Stokes, G., Smith, F., & Chaib, C. (2019) · Quality of Life Research · doi:10.1007/s11136-019-02152-6 · Cited by 50 · cited 1×
“…Europe and the in fl uence of disease stage concluded that, despite the relative paucity of data on the fi nancial burden incurred directly by patients and caregivers, the fi nancial burden of advanced NSCLC was considerable, with both direct and indirect costs increasing as disease progresses (26).”
Pagedar, N. A., Davis, A. B., Sperry, S. M., Charlton, M. E., & Lynch, C. F. (2018) · Head & Neck · doi:10.1002/hed.25521 · Cited by 48
Robsahm, T. E., Helsing, P., Nilssen, Y., Vos, L., Rizvi, S. M. H., Akslen, L. A., & Veierød, M. B. (2018) · Clinical Epidemiology · doi:10.2147/clep.s151246 · Cited by 47
Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review
Huang, M., Haiderali, A., Fox, G. E., Frederickson, A. M., Cortés, J., Fasching, P. A., & O’Shaughnessy, J. (2022) · PharmacoEconomics · doi:10.1007/s40273-021-01121-7 · Cited by 45
Social differences in lung cancer management and survival in South East England: a cohort study
Berglund, A., Lambe, M. P., Lüchtenborg, M., Linklater, K. M., Peake, M. D., Holmberg, L., & Møller, H. (2012) · BMJ Open · doi:10.1136/bmjopen-2012-001048 · Cited by 40 · cited 1×
“In 10 studies, early stage comprised of stages I-II, while stages III-IV constituted advanced stage (51 – 53, 55 – 58, 64, 66, 74).”
Huang, K., Zhang, J., Yu, Y., Lin, Y., & Song, C. (2022) · BMC Geriatrics · doi:10.1186/s12877-022-02936-5 · Cited by 38
Schwartz, K., Simon, M. S., Bylsma, L. C., Ruterbusch, J. J., Beebe‐Dimmer, J., Schultz, N. M., Flanders, S. C., Barlev, A., Fryzek, J. P., & Quek, R. G. W. (2018) · Cancer · doi:10.1002/cncr.31299 · Cited by 36
Wang, F., Mishina, S., Takai, S., Le, T. K., Ochi, K., Funato, K., Matsuoka, S., & Ohe, Y. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.04.010 · Cited by 35
Moon, P. K., Ma, Y., & Megwalu, U. C. (2022) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2022.1086 · Cited by 34
Toscano, A., Blanchin, M., Bourdon, M., Bonnaud‐Antignac, A., & Sebille, V. (2020) · Quality of Life Research · doi:10.1007/s11136-019-02401-8 · Cited by 33 · cited 2×
“In 10 studies, early stage comprised of stages I-II, while stages III-IV constituted advanced stage (51 – 53, 55 – 58, 64, 66, 74).”
Aly, A., Shah, R., Hill, K., & Botteman, M. F. (2019) · Future Oncology · doi:10.2217/fon-2018-0407 · Cited by 32
Buck, P. O., Saverno, K. R., Miller, P. J., Arondekar, B. V., & Walker, M. S. (2015) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.12.010 · Cited by 31
Snee, M., Cheeseman, S., Thompson, M., Riaz, M., Sopwith, W., Lacoin, L., Chaib, C., Daumont, M., Penrod, J. R., & Hall, G. D. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-046396 · Cited by 29
Fisher, M. D., Shenolikar, R. A., Miller, P. J., Fenton, M. J., & Walker, M. S. (2018) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2018.07.025 · Cited by 26
Omland, L. H., Lindberg, H., Carus, A., Als, A. B., Jensen, N. V., Taarnhøj, G. A., Trepiakas, R., Suetta, C., Omland, L. H., & Pappot, H. (2020) · European Urology Open Science · doi:10.1016/j.euros.2020.12.002 · Cited by 25
Triple Negative Breast Cancer in Iranian Women: Clinical Profile and Survival Study
Kashi, A. S. Y., Yazdanfar, S., Akbari, M. E., & Rakhsha, A. (2017) · International Journal of Cancer Management · doi:10.5812/ijcm.10471 · Cited by 24 · cited 2×
“…fi ve tumor types, with the highest number of publications identi fi ed for NSCLC [8 studies (63, 67, 70, 75, 76, 78, 80, 89, 91)], followed by HNC [3 studies (54, 93, 94, 116)], TNBC [1 study (74, 105 – 107)], bladder cancer [1 study (102)], melanoma [1 study (108)] and RCC [2 studies (113, 114)].”
InfluentialImpact of initial stage on metastatic melanoma survival
Wilson, M. A., Zhong, J., Rosenbaum, B. E., Utter, K., Moran, U., Darvishian, F., Polsky, D., Berman, R. S., Shapiro, R. L., Pavlick, A. C., et al. (2018) · Melanoma Research · doi:10.1097/cmr.0000000000000526 · Cited by 24
Abboud, K., Umoru, G., Esmail, A., Abudayyeh, A., Murakami, N., Al-Shamsi, H. O., Javle, M. M., Saharia, A., Connor, A. A., Kodali, S., et al. (2023) · Cancers · doi:10.3390/cancers15051433 · Cited by 24
Health‐related quality of life around the time of diagnosis in patients with bladder cancer
Yu, E. Y.-W., Nekeman, D., Billingham, L. J., James, N. D., Cheng, K. K., Bryan, R. T., Wesselius, A., & Zeegers, M. P. (2019) · British Journal of Urology · doi:10.1111/bju.14804 · Cited by 23
Ehrenstein, V., Eriksen, K., Taylor, A., Servidio, L., & Jakobsen, E. H. (2022) · Cancer Medicine · doi:10.1002/cam4.4946 · Cited by 21 · cited 3×
“(Figure 3) (63, 67, 70, 75, 76, 80, 89, 108).”
Survival After Lip Cancer Diagnosis
Sargeran, K., Murtomaa, H. T., Safavi, S. M. R., Vehkalahti, M. M., & Teronen, O. P. (2009) · Journal of Craniofacial Surgery · doi:10.1097/scs.0b013e31818431bd · Cited by 19 · cited 3×
“Of the six included studies that reported mOS and OS rates, two reported mOS (95, 96), whereas three included OS rates 5 years post-diagnosis (54, 93, 94).”
Differences in melanoma outcomes among Hispanic Medicare enrollees
Rouhani, P., Arheart, K. L., & Kirsner, R. S. (2010) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2009.11.594 · Cited by 19
Humanistic burden of disease for patients with advanced melanoma in Canada
Cheung, W. Y., Bayliss, M. S., White, M. K., Stroupe, A., Lovley, A., King‐Kallimanis, B. L., & Lasch, K. (2018) · Supportive Care in Cancer · doi:10.1007/s00520-017-4025-9 · Cited by 18 · cited 1×
“In a Canadian study, consisting of 29 interviews with patients suffering from advanced melanoma (stage III and IV), patients noted greatly diminished overall functioning and quality of life by the time they reached advanced stage disease (24).”
Haiderali, A., Rhodes, W., Gautam, S., Huang, M., Sieluk, J., Skinner, K. E., & Schwartzberg, L. S. (2021) · Future Oncology · doi:10.2217/fon-2021-0530 · Cited by 17
Amiri, M., Sofimajidpour, H., Esmaeilnasab, N., Khoubi, J., Ghaderi, E., & Roshani, D. (2020) · BMC Urology · doi:10.1186/s12894-020-00769-1 · Cited by 15
Soares, M., Antunes, L., Redondo, P., Borges, M., Hermans, R., Patel, D., Grimson, F., Munro, R. E. J., Chaib, C., Lacoin, L., et al. (2021) · Lung Cancer Management · doi:10.2217/lmt-2020-0028 · Cited by 15
Russell, B. A., Liedberg, F., Hagberg, O., Ullén, A., Söderkvist, K., Ströck, V., Aljabery, F. A.-S., Gårdmark, T., Jerlström, T., Sherif, A. M., et al. (2021) · Scandinavian Journal of Urology · doi:10.1080/21681805.2021.2002399 · Cited by 15
Klarenbeek, S. E., Aarts, M. J., van den Heuvel, M. M., Prokop, M., Tummers, M., & Schuurbiers, O. C. J. (2022) · Thorax · doi:10.1136/thoraxjnl-2021-218059 · Cited by 15
Auluck, A., Hislop, G., Bajdik, C. D., Hay, J. H., Bottorff, J. L., Zhang, L., & Rosin, M. P. (2012) · Cancer Causes & Control · doi:10.1007/s10552-012-0065-0 · Cited by 14
Lehrberg, A. V., Davis, M. B., Baidoun, F., Petersen, L. F., Susick, L. L., Jenkins, B. D., Chen, Y., Ivanics, T., Rakitin, I., Bensenhaver, J. M., et al. (2021) · The Breast Journal · doi:10.1111/tbj.14225 · Cited by 14
Estimating Cost Savings from Early Cancer DiagnosisPreprint
Kakushadze, Z., Raghubanshi, R., & Yu, W. (2017) · SSRN Electronic Journal · doi:10.2139/ssrn.2975597 · Cited by 12
Haiderali, A., Rhodes, W., Gautam, S., Huang, M., Sieluk, J., Skinner, K. E., & Schwartzberg, L. S. (2021) · Future Oncology · doi:10.2217/fon-2021-0531 · Cited by 11
Kida, N., Morishima, T., Tsubakihara, Y., & Miyashiro, I. (2022) · The Nephron journals/Nephron journals · doi:10.1159/000521603 · Cited by 9
(2019) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12834 · Cited by 9
Li, X., Xu, Z., Xu, T., Qi, F., & Song, N. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s340284 · Cited by 8
Impact of microvascular invasion on 5-year overall survival of resected non-small cell lung cancer
Monteiro, A. S., a, S. R. D. C. A., Araújo, L. H., & de Souza, M. C. (2022) · Jornal Brasileiro de Pneumologia · doi:10.36416/1806-3756/e20210283 · Cited by 8 · cited 5×
“The studies that categorized speci fi c sub-stages or the entirety of stage III as part of the early stage were primarily conducted in patients diagnosed either with NSCLC (six studies) (63, 65, 67 – 70) or TNBC (three studies) (71 – 73).”
InfluentialDijksterhuis, W. P. M., Kroese, T. E., Verhoeven, R. H. A., van Rossum, P. S. N., Mook, S., Mohammad, N. H., Hulshof, M. C. C. M., Gisbertz, S. S., Ruurda, J. P. H., van Oijen, M. G. H., et al. (2022) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2022.03.003 · Cited by 7
Lin, H. M., Pan, X., Biller, A., Covey, K. J., Huang, H., Sugarman, R., Scipione, F., & West, H. (2020) · Lung Cancer Management · doi:10.2217/lmt-2020-0018 · Cited by 6
Therapeutic outcomes of oral cancers at Kyoto University Hospital
Nishida, A. T., Tanaka, S., Hirano, S., Tamura, Y., Tamaki, H., Asato, R., & Ito, J. (2007) · Acta Oto-Laryngologica · doi:10.1080/00016480601067958 · Cited by 5
Azzouqa, A., Chen, R., Lou, Y., Ailawadhi, S., & Manochakian, R. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.9058 · Cited by 5 · cited 1×
“In NSCLC, 23 studies reported data on OS, with 15 reporting mOS (64, 70, 81 – 83, 85 – 92) and 8 providing OS rates (63, 70, 75, 76, 78, 80, 89, 91) 5 years post-diagnosis for patients diagnosed with NSCLC by stage at diagnosis.”
Davies, F. J., Knott, C. S., Kerr, C., Adedokun, L., & Lockhat, D. (2020) · Value in Health · doi:10.1016/j.jval.2020.08.466 · Cited by 5
Dao, T. V., Diep, T. B., Phuong, T. L., Huggenberger, R., & Kumar, A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.842296 · Cited by 5
Martin, C. M., Guerrero, A. P., Mas-López, L., Campos-Gómez, S., Francisco, O., Gallegos, L. F. T., & Huggenberger, R. (2022) · Cancer Medicine · doi:10.1002/cam4.4990 · Cited by 5
Changes in treatment trends in the early glottic cancer population after the Affordable Care Act
Panuganti, B. A., Stuart, E. R., & Weissbrod, P. A. (2020) · Head & Neck · doi:10.1002/hed.26463 · Cited by 4 · cited 1×
“In 10 studies, early stage comprised of stages I-II, while stages III-IV constituted advanced stage (51 – 53, 55 – 58, 64, 66, 74).”
Tjokrowidjaja, A., Browne, L. H., & Soudy, H. (2021) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13689 · Cited by 4
Abrão, F. C., de Abreu, I. R. L. B., Silva, V. G., Rosamilia, G. D. A., Peres, S. V., Hanriot, R. D. M., & Younes, R. N. (2022) · Journal of Surgical Oncology · doi:10.1002/jso.27015 · Cited by 4
Haas, N. B., Bhattacharya, R., Song, Y., Rogerio, J., Zhang, S., Carley, C., Anderson, A., Signorovitch, J., & Sundaram, M. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.16_suppl.4543 · Cited by 4
Vachani, A., Johnson, B. H., JOHNSTON, S., Johnson, W. E., Chandran, U., Sengupta, N., Laxmanan, B., & Kalsekar, I. D. (2021) · CHEST Journal · doi:10.1016/j.chest.2021.07.1468 · Cited by 3
Disease-free and overall survival outcomes for localized RCC patients by disease stage.
Haas, N. B., Bhattacharya, R., Ogbomo, A. S., Imai, K., Gautam, S., Rogerio, J., Yu, R. S. H., Chhabra, J., & Sundaram, M. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.16_suppl.e16526 · Cited by 3
Ekman, S., Sørensen, J., Brustugun, O. T., Horvat, P., Patel, D., Rosenlund, M., Kejs, A. M. T., Juarez-Garcia, A., Daumont, M., Lacoin, L., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz070.005 · Cited by 2
Luciano, S., Haudenschild, C. D., & Kuranz, S. P. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.e21715 · Cited by 2
Hochfelder, C. G., McGinn, A. P., Mehta, V., Castellucci, E., Kabarriti, R., & Ow, T. J. (2020) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2020.07.313 · Cited by 2
Sørup, S., Darvalics, B., Kearney, M., Madmoudpour, S. H., Oksen, D., Kolitsopoulos, F. M., Agerbæk, M., & Cronin-Fenton, D. P. (2021) · Value in Health · doi:10.1016/j.jval.2021.04.332 · Cited by 2
MA08.02 Outcomes of Early Stage ALK-positive NSCLC patients in a Real-World Cohort
Schmid, S., Chotai, S., Cheng, S. H., Zhan, L. J., Balaratnam, K., Khan, K., Patel, D., Brown, M. C., Xu, W., Moriarty, P., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.08.147 · Cited by 2
Kaliadzich, Z. V., Макаревич, М. Н., & Evmenenko, A. A. (2019) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(19)30321-4 · Cited by 1 · cited 1×
“…fi ve tumor types, with the highest number of publications identi fi ed for NSCLC [8 studies (63, 67, 70, 75, 76, 78, 80, 89, 91)], followed by HNC [3 studies (54, 93, 94, 116)], TNBC [1 study (74, 105 – 107)], bladder cancer [1 study (102)], melanoma [1 study (108)] and RCC [2 studies (113, 114)].”
Šuipytė, J., Schmidt, S., Herrmann, C., Mousavi, S. M., Hitz, F., & Früh, M. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz260.100 · Cited by 1
Role of T0 status in overall survival for unresectable stage III non-small cell lung cancer.
Komiya, T., Powell, E., Vu, C. C., & Guddati, A. K. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.9026 · Cited by 1 · cited 3×
“(Figure 3) (63, 67, 70, 75, 76, 80, 89, 108).”
1150P Long-term outcomes of stage IIB-IV melanoma patients: Nationwide data from Norway
Winge-Main, A., Robsahm, T. E., Nyakas, M., Festervoll, G., Torkilseng, E. B., Thybo, S., Pati, S., & Carroll, R. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.1273 · Cited by 1
Greystoke, A., Nawaz, A. U., Ferguson, S., Pabla, M., Sanjeevi, P., & Bar-Ziv, O. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.01.451 · Cited by 1
Aragon‐Ching, J. B., & Wang, H. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.e16582 · Cited by 1
Neto, F. L., de Sousa, L. G., Johnson, F. M., Lee, J. J., Frank, S. J., Moreno, A. C., Dahlstrom, K. R., & Ferrarotto, R. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.6067 · Cited by 1
Population-based impacts of new therapies on outcomes for stage IV non-small cell lung cancer.
Rittberg, R., Bucher, O., Xue, L., Aurangzeb, Z., Banerji, S. O., & Dawe, D. E. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.9120 · Cited by 1
P-216 Impact of delay in treatment initiation in Overall Survival in Head and Neck Cancer
Amarillo, D., Herrera, G., Lara, G., Muñóz, E., Sanchez, S., Sommer, P., Sosa, S., Alvarez, D. R. B., Borche, G., Munyo, A., et al. (2021) · Oral Oncology · doi:10.1016/s1368-8375(21)00499-1 · Cited by 1
Analysis of Patient Reported Outcomes for Stage IV Non-Small Cell Lung Cancer Patients in Ontario
Tjong, M. C., Doherty, M. K., Tan, H., Chan, W. C., Zhao, H., Hallet, J. I., Darling, G. E., Kidane, B., Wright, F., Mahar, A. L., et al. (2021) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2021.07.640 · Cited by 1
Abrão, F. C., Peres, S. V., de Abreu, I. R. L. B., & Younes, R. N. (2021) · Journal of Thoracic Disease · doi:10.21037/jtd-21-1071 · Cited by 1
Gogate, A., Crosbie, A., Le, T. K., Zhang, Y., Das, R., & Davis, C. (2022) · Cancer Research · doi:10.1158/1538-7445.sabcs21-p3-12-15 · Cited by 1
Cerqueira, E., Padula, A., Alencar, F. O., Rego, M., de Almeida, M. D. B., Batista, P. D. M., Arinelli, R., Calabrich, A., & Schvartsman, G. (2022) · Value in Health · doi:10.1016/j.jval.2022.04.803 · Cited by 1
Research works printed but not linked: 7
- 15. Kuznar W. Targeted agents, immunotherapies are advancing to the adjuvant setting in solid tumors. Targeted Therapies Oncol. (2021) 10(12):32.
- 16. National Academies of Sciences Engineering and Medicine. Chapter: 9. Federal programs that support cancer prevention and early detection. In: Fulfilling the Potential of Cancer Prevention and Early Detection. Washington, DC: The National Academies Press; (2003).
- 50. Tulyaeva AB, Iztleuov YM, Balmagambe-Tova SK, Koyshybaev AK, Djussembekov ST, Aitmagambetova MA. Five-year survival in young patients diagnosed with gastric cancer comparing to the older groups in the Aktobe province of western Kazakhstan within 2013-2017. Minerva Medica;. (2019) 110(Suppl. 1; 2):86.30667207
- 80. Kalilani L, Chao J, Hogea C, Stojadinovic A, Giove TJ, Sun X, et al. Recent Estimates of Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) in the US (2010-2020). The International Society for Pharmacoeconomics and Outcomes Research (ISPOR). (2022) 25(1):S4.
- 103. Sieluk J, Haiderali A, Huang M, Yang L, Tryfonidis K, Hirshfield KM. SEER-Medicare study of early-stage triple-negative breast cancer: Real-world treatment patterns, survival, and expenditures 2010 to 2016. J Clin Oncol. (2020) 38(15). doi: 10.1200/JCO.2020.38.15_suppl.e125 · doi:10.1200/jco.2020.38.15_suppl.e125
- 110. Ramond A, Carroll R, Vekeria S, Nordstrom B. Investigating Secular Trends in the Survival of Melanoma Patients in England. The International Society for Pharmacoeconomics and Outcomes Research (ISPOR. Value in Health (2021) 24:S40.
- 121. Aly A, Johnson C, Doleh Y, Shenolikar R, Hussain A. Lifetime costs of urothelial carcinoma by stage at diagnosis. J Managed Care Specialty Pharm. (2019) 25(3a):S31.
Cited by
The Health Impact of Using Anti-PD-1 Agents to Treat Early-Stage Cancer in Belgium
Bento‐Abreu, A., Vandekeere, S., Sönmez, D., Neves, C., Mantaian, T., Ethgen, O., & Aguiar‐Ibáñez, R. (2025) · Oncology and Therapy · doi:10.1007/s40487-025-00357-z · Cited by 7
Self-citationDiagnostic accuracy of teledermatology for skin diseases: a systematic review and meta-analysis
Martyin, K., Meznerics, F. A., Bokor, L. A., Szabó, B., Hegyi, P., Kiss, N., & Bánvölgyi, A. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1739592 · Cited by 4
“As melanoma has the highest mortality among skin cancers, particularly when diagnosis is delayed, early detection is crucial to promote public health, reduce economic costs of health care, and improve patient outcomes (180, 181).”
A cross-sectional assessment of US cancer diagnoses during the COVID-19 pandemic
Burus, T., Kim, U., Rose, J., Koroukian, S. M., & Kuhs, K. A. L. (2025) · Cancer Epidemiology · doi:10.1016/j.canep.2025.102944 · Cited by 3
Rationale and recommendations for improving early-stage oncology diagnosis, treatment, and access
Aguiar‐Ibáñez, R., Goldschmidt, D., Zhou, Z., Eales, J., Peters, S., Cardoso, F., Ciani, O., Arunachalam, A., Haiderali, A., Roediger, A., et al. (2026) · Journal of Medical Economics · doi:10.1080/13696998.2026.2623775 · Cited by 3
Self-citationAkpe, V., & Cock, I. E. (2025) · Preprints.org · doi:10.20944/preprints202509.0304.v1 · Cited by 3
Metadata
- Authors
- Aguiar-Ibáñez, R., Mbous, Y. P. V., Sharma, S., & Chawla, E.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- PAREXEL International (India) (IN)
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2025-03-19
- Volume
- 15
- Pages
- 1546447-1546447
- ISSN
- 2234-943X (ISSN-L)
- PMC
- PMC11962897
- OpenAlex
- W4408621175
- Cited by
- 17
- References
- 107
- Citations by year
- 2026: 13 · 2025: 4
- FWCI
- 2.00
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Oncology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- early cancer detection, cancer stage at diagnosis, cancer screening, overall survival, health-related quality of life, healthcare resource utilization, health care costs, bladder cancer, gastric cancer, head and neck cancer, melanoma, non-small cell lung cancer, renal cell carcinoma, triple-negative breast cancer, tumor grade
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.